Stem Cell Secretome as an Emerging Approach for Parkinson’s Disease

Parkinson's Disease (PD) is a chronic nervous system disorder that affects the patient’s movement. Symptoms will usually start gradually, with tremors being the most common symptom, but the disorder can also cause stiffness or slowed down movement.

A certain genetic predisposition in combination with environmental factors are most likely responsible for the neuronal degeneration that causes Parkinson’s Disease. It is thought that several factors on a cellular level, including mitochondrial dysfunction, oxidative stress and a dysfunctional protein degradation machinery, play a crucial role in PD.

To date, there is no cure for Parkinson’s Disease. Currently available therapeutic strategies are largely symptomatic rather than disease-modifying and, like other medicines, may be associated with side effects. There is therefore continued interest in developing new therapeutic approaches for PD. Cellular dopamine-replacement approaches have been proposed as the basis for PD therapies thirty years ago1, but results were not consistent. The use of stem cells has attracted growing scientific interest, as research has identified regenerative, self-renewing and anti-apoptotic properties. Within the scope of a replacement strategy, several types of stem cell sources are being investigated, amongst them mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells and neural stem cells.

Current research suggests that much of the activity associated with stem cells may be mediated not by the cells themselves, but by their secreted components in the form of microvesicles or exosomes2. The sum of all secreted compounds, called the Stem Cell Secretome, is considered a main contributor to this activity. A recent scientific review article3 summarized ongoing clinical trials and other research efforts investigating stem cell implantation and stem cell approaches for Parkinson's Disease. While long-term data are still lacking, the reported early findings are encouraging and point to the potential of the cell secretome as a cell-free approach worth further investigation in PD.

The authors further argue that a full characterization of the secretome, as well as disease-specific modulation of the secretome are important next steps in advancing this approach. In combination with other treatments, it may in future help to improve the treatment options available for Parkinson’s Disease.

References

  1. Parmar M, Torper O, Drouin-Ouellet J. Cell-based therapy for Parkinson’s disease: a journey through decades toward the light side of the force. Eur J Neurosci. 2018;55:4763–4776.
  2. Teixeira, F. G., Carvalho, M. M., Sousa, N., & Salgado, A. J. (2013). Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?. Cellular and Molecular Life Sciences, 70(20), 3871-3882.
  3. Marques, C. R., Marote, A., Mendes-Pinheiro, B., Teixeira, F. G., & Salgado, A. J. (2018). Cell secretome based approaches in Parkinson’s disease regenerative medicine. Expert opinion on biological therapy, 18(12), 1235-1245.

News & Insights

Patient Services at ANOVA Institute for Regenerative Medicine

  • Located in the center of Germany, quick access by car or train from anywhere in Europe
  • Simple access worldwide, less than 20 minutes from Frankfurt Airport
  • Individualized therapy with state-of-the-art autologous stem cell products
  • Individually planned diagnostic work-up which include world-class MRI and CT scans
  • German high quality standard on safety and quality assurance
  • Personal service with friendly, dedicated Patient Care Managers
  • Continuous analysis of scientific data in the field of regenerative medicine